CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study (vol 13, 44, 2023)

被引：0
|
作者：
Niu, Jiahua [1 ,2 ]
Qiu, Huiying [1 ,2 ]
Xiang, Fang [3 ]
Zhu, Lin [3 ]
Yang, Jun [1 ,2 ]
Huang, Chongmei [1 ,2 ]
Zhou, Kun [1 ,2 ]
Tong, Yin [1 ,2 ]
Cai, Yu [1 ,2 ]
Dong, Baoxia [1 ,2 ]
Lu, Yuan [3 ]
Sun, Xuedong [3 ]
Wan, Liping [1 ,2 ]
Ding, Xueying [2 ]
Wang, Haopeng [4 ]
Song, Xianmin [1 ,2 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Hematol, Shanghai, Peoples R China
[2] Shanghai Sci & Technol Comm STCSM, Engn Technol Res Ctr Cell Therapy & Clin Translat, Shanghai, Peoples R China
[3] Hrain Biotechnol, Shanghai, Peoples R China
[4] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China
来源：
BLOOD CANCER JOURNAL | 2023年 / 13卷 / 01期
基金：
国家重点研发计划;
关键词：
D O I：
10.1038/s41408-023-00825-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia
    Yang, Junfang
    Li, Jianqiang
    Zhang, Xian
    Lv, Fanyong
    Guo, Xiaoling
    Wang, Qinglong
    Wang, Lin
    Chen, Dandan
    Zhou, Xiaosu
    Ren, Jinhai
    Lu, Peihua
    BLOOD, 2018, 132
  • [42] Efficacy and Safety of CD28-or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
    Zhao, Xiangyu
    Yang, Junfang
    Zhang, Xian
    Lu, Xin-An
    Xiong, Min
    Zhang, Jianping
    Zhou, Xiaosu
    Qi, Feifei
    He, Ting
    Ding, Yanping
    Hu, Xuelian
    De Smet, Floris
    Lu, Peihua
    Huang, Xiaojun
    MOLECULAR THERAPY-ONCOLYTICS, 2020, 18 : 272 - 281
  • [43] Tandem CD19/CD22 Dual Targets CART Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study
    Cui, Wei
    Zhang, Xinyue
    Dai, Haiping
    Cui, Qingya
    Song, Baoquan
    Wu, Depei
    Tang, Xiaowen
    Yin, Jia
    Li, Zheng
    BLOOD, 2020, 136
  • [44] Targeting B Cell Precursor Acute Lymphoblastic Leukemia (ALL) with Chimeric Antigen Receptors (CARs) Specific for CD19 or CD22
    Orentas, Rimas J.
    Haso, Waleed
    Lee, Daniel W.
    Fry, Terry J.
    Wayne, Alan S.
    Mackall, Crystal L.
    MOLECULAR THERAPY, 2013, 21 : S125 - S125
  • [45] Effect of CD22-directed CAR-T cells secreting anti-CD19 T cell engagers on control of leukemia progression compared to tandem anti-CD19/CD22 CAR-T cells.
    Arroyo-Rodenas, Javier
    Diez-Alonso, Laura
    Falgas, Aida
    Martinez-Moreno, Alba
    Gil-Etayo, Francisco Javier
    Aguilar-Sopena, Oscar
    Velasco-Sidro, Miriam
    Bravo-Martin, Clara
    Ramirez-Fernandez, Angel
    Jimenez-Reinoso, Anais
    Blanco, Belen
    Roda-Navarro, Pedro
    Bueno, Clara
    Menendez, Pablo
    Alvarez-Vallina, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells
    Grain, Audrey
    Ollier, Jocelyn
    Guillaume, Thierry
    Chevallier, Patrice
    Le Calvez, Baptiste
    Eveillard, Marion
    Clemenceau, Beatrice
    BIOMEDICINES, 2023, 11 (02)
  • [47] Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
    Perica, Karlo
    Flynn, Jessica
    Curran, Kevin J.
    Rivere, Isabelle
    Wang, Xiuyan
    Senechal, Brigitte
    Halton, Elizabeth
    Diamonte, Claudia
    Pineda, John
    Bernal, Yvette
    Gonen, Mithat
    Sadelain, Michel
    Brentjens, Renier J.
    Park, Jae H.
    LEUKEMIA, 2021, 35 (11) : 3268 - 3271
  • [48] Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
    Karlo Perica
    Jessica Flynn
    Kevin J. Curran
    Isabelle Rivere
    Xiuyan Wang
    Brigitte Senechal
    Elizabeth Halton
    Claudia Diamonte
    John Pineda
    Yvette Bernal
    Mithat Gonen
    Michel Sadelain
    Renier J. Brentjens
    Jae H. Park
    Leukemia, 2021, 35 : 3268 - 3271
  • [49] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Sining Liu
    Xinyue Zhang
    Haiping Dai
    Wei Cui
    Jia Yin
    Zheng Li
    Xiao Yang
    Chunxiu Yang
    Shengli Xue
    Huiying Qiu
    Miao Miao
    Suning Chen
    Zhengming Jin
    Chengcheng Fu
    Caixia Li
    Aining Sun
    Yue Han
    Ying Wang
    Lei Yu
    Depei Wu
    Qingya Cui
    Xiaowen Tang
    Blood Cancer Journal, 13
  • [50] CD4+CD25+CD127low regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia
    Pan, Ying
    Wang, Huiping
    An, Furun
    Wu, Fan
    Tao, Qianshan
    Li, Yingwei
    Ruan, Yanjie
    Zhai, Zhimin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 96
12345